These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 17211535)
21. Adjuvant endocrine treatment of early breast cancer. Lønning PE Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446 [TBL] [Abstract][Full Text] [Related]
23. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer. Jones LW; Haykowsky M; Pituskin EN; Jendzjowsky NG; Tomczak CR; Haennel RG; Mackey JR Oncologist; 2007 Oct; 12(10):1156-64. PubMed ID: 17962609 [TBL] [Abstract][Full Text] [Related]
24. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005. Smith IE; Arnedos M Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939 [TBL] [Abstract][Full Text] [Related]
25. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Abdulhaq H; Geyer C Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594 [TBL] [Abstract][Full Text] [Related]
26. Breast cancer adjuvant endocrine therapy. Cigler T; Goss PE Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763 [TBL] [Abstract][Full Text] [Related]
27. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958 [TBL] [Abstract][Full Text] [Related]
30. SERMs: meeting the promise of multifunctional medicines. Jordan VC J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726 [TBL] [Abstract][Full Text] [Related]
31. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. Chlebowski RT Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792 [TBL] [Abstract][Full Text] [Related]
32. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard]. Jonat W MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996 [No Abstract] [Full Text] [Related]
33. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Monnier AM Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927 [TBL] [Abstract][Full Text] [Related]
34. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cuppone F; Bria E; Verma S; Pritchard KI; Gandhi S; Carlini P; Milella M; Nisticò C; Terzoli E; Cognetti F; Giannarelli D Cancer; 2008 Jan; 112(2):260-7. PubMed ID: 18041059 [TBL] [Abstract][Full Text] [Related]
35. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature. Lycette JL; Luoh SW; Beer TM; Deloughery TG Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073 [TBL] [Abstract][Full Text] [Related]
36. The effects of aromatase inhibitors on lipids and thrombosis. Bundred NJ Br J Cancer; 2005 Aug; 93 Suppl 1(Suppl 1):S23-7. PubMed ID: 16100522 [TBL] [Abstract][Full Text] [Related]
37. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle? Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345 [TBL] [Abstract][Full Text] [Related]
38. Vascular effects of aromatase inhibitors: data from clinical trials. Howell A; Cuzick J J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188 [TBL] [Abstract][Full Text] [Related]
39. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review. Poole R; Paridaens R Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453 [TBL] [Abstract][Full Text] [Related]